FDA clears Axis-Shield's rheumatoid arthritis test
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for Axis-Shield's anti-CCP test for rheumatoid arthritis (RA). The diagnostic, which runs on Abbott's Architect family of analysers, detects antibodies to cyclic citrullinated peptide (CCP), which can appear in patients' blood before symptoms start. Dundee, UK-based Axis-Shield claims that its test is more specific than rheumatoid factor, a traditional diagnostic for RA. Anti-CCP testing is gaining acceptance, with the European League Against Rheumatism adding it to its diagnostic criteria for early-stage RA. Axis-Shield has an estimated a 40% share of this market, with about five million tests carried out per year. Abbott launched the test outside the US in January 2009, and will introduce it in the US later this month.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.